Tachibana N

No ORCID on file · 3 papers in corpus · active 2019-2023

Study types

  • article 1
article 2023
The addition of dydrogesterone improves the outcomes of pregnant women with low progesterone levels when receiving vaginal progesterone alone as luteal support in HRT‐FET cycles
Reproductive medicine and biology ·doi:10.1002/rmb2.12511

Purpose: Vaginal progesterone (VP) alone has been used as luteal support (LS) in HRT-FET cycles without measuring serum progesterone concentrations (SPC) because it can achieve adequate intrauterine progesterone levels. However, several rep…

2022
A novel orally active gonadotropin-releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology.
Reproductive medicine and biology ·doi:10.1002/rmb2.12424

PurposeTo evaluate the efficacy of an oral gonadotropin-releasing hormone antagonist (GnRH Ant), relugolix (R), for assisted reproductive technology (ART).MethodsWe enrolled women undergoing ART using a GnRH Ant for controlled ovarian stimu…

2019
Different anti-Műllerian hormone (AMH) levels respond to distinct ovarian stimulation methods in assisted reproductive technology (ART): Clues to better ART outcomes.
Reproductive medicine and biology ·doi:10.1002/rmb2.12270

PurposeWe asked whether the relationship between anti-Műllerian hormone (AMH) value and the response to ovarian stimulation (OS) might be AMH value-related and differ for each regimen, aiming at getting clues as to how to choose OS protocol…